Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
PepMetics® (peptide mimetics)
Applicable field (uses covered by this announcement)
IR for individual investors, biotechnology industry, novel drug development, drug discovery
Launch date7 October 2026 (scheduled, seminar date)
Relationship between the counterparty and the company
PRISM BioLab Co.,LTD206A
Relationship with the Company
Relationship between the organizer of the IR seminar and the presenting company.
CounterpartyLogmi Finance
Organizer of the online IR seminar for individual investors. Other company details: Not disclosed.
Offering price
Participation fee: Free
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | PepMetics® (peptide mimetics) |
| Counterparty | Logmi Finance |
| Counterparty overview | Organizer of the online IR seminar for individual investors. Other company details: Not disclosed. |
| Relationship with the Company | Relationship between the organizer of the IR seminar and the presenting company. |
| Offering price | Participation fee: Free |
| Launch date | 7 October 2026 (scheduled, seminar date) |
| Applicable area | IR for individual investors, biotechnology industry, novel drug development, drug discovery |
Items this document does not state (11)
Contract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote dialogue with shareholders and investors and create opportunities to deepen understanding of the company through active IR activities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.